Multi-Stakeholder Meetings

 Call for Expression of Interest

conect4children is pleased to announce that the fourth c4c International Multi-Stakeholder Meeting (MSM) will address the topic perinatal asphyxia. The meeting will be a hybrid meeting that will take place on 18 and 19 September 2023, ahead of the 5^th jENS (joint European Neonatal Societies) conference in Rome. 

Who can participate?

International academic experts in perinatal asphyxia, experts in neonatal preclinical and biomarker research, representatives from pharmaceutical companies developing relevant assets, representatives from regulators (EMA, FDA) and patients, parents and their advocates. The meeting will be on invitation only. Interested participants can apply by filling the Expression of Interest form available here.

Deadline for submission: 30 July 2023 !       Want to know more? CLICK HERE! 

A 3rd c4c Multistakeholder Meeting (MSM) was held on 21 February in Berlin; the topic was medical devices for children with Type 1 diabetes. The aim of the meeting was to define the unmet medical needs, understand the regulatory environment in the EU and US and learn about the challenges faced by industry when developing devices for children. The strategic discussion identified actions to promote access to medical devices for all children of all ages. MSMs are designed to facilitate discussion and interaction among relevant stakeholders on the development of medicines in the best interest of children and adolescents. More details of the outcome of this MSM will soon be available on the c4c website.

Read the meeting report here!

On 1-2 March 2022, c4c hosted a successful 2^nd online c4c Multi-Stakeholder Meeting on paediatric Atopic Dermatitis (AD). Many thanks to speakers, the Programme Committee and to the 100 participants from academia, regulatory bodies, young patients, advocates and industry representatives. Presentations included biology/immunology of AD in children, perspective from young patients and families and description of industry assets. Over 60 drugs in clinical development or approved were identified.  Panel discussions focused on paediatric unmet medical needs and improvement of the evaluation of new medicines for children and adolescents. A scientific manuscript for a specialized journal is currently in development.

Read the meeting report here!